This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove 2015 Remove Clinical Pharmacology Remove Small Molecule Related Topics
Pharmacokinetics Drug Development Regulations Pharmacy Packaging Therapies Clinical Development Trials Treatment Disease More Related Topics >
article thumbnail

Analysis Life Sciences Thank You Workshop addresses oncology dose optimization across full span of development

Agency IQ

FEBRUARY 23, 2024

Additionally, this approach is generally no longer applicable to new treatments that are more targeted in their effects, such as immunotherapies and targeted small molecule therapies. This workshop built on three prior workshops held by the FDA-AACR, which took place in 2015, 2016 and 2017.

Science 40
Science FDA Trials Clinical Pharmacology 40
article thumbnail

Analysis Life Sciences Thank You The FDA and oncology: 2023 year in review

Agency IQ

DECEMBER 11, 2023

In 2015, the FDA, along with the American Association for Cancer Research (AACR), held a workshop on dose optimization for small molecules. Despite challenges in enrolling pediatric patients with rare cancers in trials, KRISTEN WESSEL of the FDA’s Division of Clinical Pharmacology recently argued that it’s not impossible.

FDA 40
FDA Science Clinical Trials Trials 40
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 42,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024